Reduced Viral Shedding Time in High-Risk COVID-19 Patients Infected by Omicron and Treated with Paxlovid: A Real-World Study from China
Wei Yang,Yahui Peng,Changsong Wang,Hongliu Cai,Lina Zhang,Jun Xu,Yongjie Wang,Maonan Wang,Mingyan Zhao,Kaijiang Yu
DOI: https://doi.org/10.2147/idr.s443574
2024-03-30
Infection and Drug Resistance
Abstract:Wei Yang, 1, &ast Yahui Peng, 1, &ast Changsong Wang, 1, &ast Hongliu Cai, 2 Lina Zhang, 3 Jun Xu, 2 Yongjie Wang, 4 Maonan Wang, 4 Mingyan Zhao, 1 Kaijiang Yu 1 1 Department of Critical Care Medicine, the First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, People's Republic of China; 2 Department of Critical Care Medicine, the First Affiliated Hospital, Zhejiang University, Hangzhou, People's Republic of China; 3 Department of Critical Care Medicine, Xiangya Hospital Central South University, Changsha, Hunan Province, People's Republic of China; 4 Department of Critical Care Medicine, Jilin Province People's Hospital, Changchun, Jilin Province, People's Republic of China &astThese authors contributed equally to this work Correspondence: Kaijiang Yu; Mingyan Zhao, Departments of Critical Care Medicine, the First Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, Heilongjiang, 150001, People's Republic of China, Email ; Introduction: The purpose of this study was to compare the viral shedding time in patients infected with the Omicron variant during Paxlovid therapy and conventional therapy and to analyze the effects of Paxlovid on patients infected with COVID-19. Methods: In this study, the demographic and clinical characteristics and laboratory data of 3159 patients infected with the SARS-CoV-2 Omicron variant treated at Jilin Province People's Hospital were collected and analyzed. A total of 362 patients received Paxlovid therapy, and 2797 patients received conventional therapy. After propensity score matching (PSM), 1086 patients were obtained. Results: The difference in platelet (PLT) count between the two groups was statistically significant but within the normal range ( P < 0.05). CT value revealed that the nucleic acid test results became negative more quickly in the Paxlovid therapy group. Analysis of the Paxlovid therapy group showed that IgG and IgM levels were increased after Paxlovid therapy administration. Conclusion: The CT value of the Paxlovid therapy group became negative more quickly. This finding suggests that Paxlovid treatment after early diagnosis of the Omicron variant may achieve good therapeutic efficacy. Keywords: Paxlovid, Omicron variant, a retrospective study, N-CT At the end of 2019, an outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occurred in China and spread rapidly worldwide. 1–3 On March 11, 2020, the World Health Organization (WHO) designated coronavirus disease 2019 (COVID-19) a global pandemic. 4 As of May 5, 2022, approximately 515 million cases of COVID-19 have been reported, resulting in 6.26 million deaths ( https://www.worldometers.info/coronavirus/ ). The COVID-19 pandemic has caused enormous mortality and severe morbidity in developed and developing countries. Currently, 5 variants, Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2) and Omicron (B.1.1.529), have been reported. 5 After replacing Delta, Omicron variants became the main variant worldwide, with a significantly greater spread than other variants. 6,7 The prevalence of Omicron variants poses more significant challenges for pandemic prevention and control. Omicron has three lineages, BA.1 (B.1.1.529.1), BA.2 (B.1.1.529.2), and BA.3 (B.1.1.529.3), first discovered in South Africa in November 2021. 8 The high transmissibility of Omicron variants is a major cause of global concern. Since the advent of Omicron, it has rapidly replaced Delta as the dominant strain worldwide. In the US, Delta accounted for 99% of the new cases on December 4, 2021. However, Omicron accounted for more than 95% of cases by January 8, 2022. 9 The basic reproductive number (R0) of the Delta variant was between 6 and 7. 10 Omicron is 3.2 times more transmissible than delta and has a 3-day doubling time. 11 In contrast, although Omicron is remarkably more frequent than Delta and previous Omicron variants, the virulence of Omicron was markedly lower than that of Delta and reinfections during the Omicron transmission period were clinically milder. 12,13 The oral antiviral drug candidate Paxlovid (PF-07321332+ritonavir), has only recently been developed by Pfizer, Inc. Paxlovid provides new hope for treating patients at risk of progressing to severe COVID-19 in the era of the Omicron variant. 14 Paxlovid is a therapeutic combination of two compounds: PF-07321332, an oral covalent 3CL protease inhibitor of SARS-CoV-2, and ritonavir, an inh -Abstract Truncated-
pharmacology & pharmacy,infectious diseases